2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

101. Red Cells and Erythropoiesis, Excluding Iron: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Genetic Disorders, Hemoglobinopathies, Thalassemia, Immunology, Autoimmune Hemolytic Anemia, Infectious Diseases, Myeloid Malignancies, Metabolic Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1099 Biological and engineering optimization of a hollow-fiber bioreactor for high-density production of lab-grown red blood cells

Shirisha Desai, Jessica Chumsky, MD2, Shouping Zhang3, Eric Bouhassira, PhD4
1 Albert Einstein College of Medicine of Yeshiva University, Bronx, New York, United States
2 Albert Einstein College of Medicine of Yeshiva University, Bronx, New York, United States
3 Albert Einstein College of Medicine of Yeshiva University, Bronx, New York, United States
4 Albert Einstein College of Medicine of Yeshiva University, Bronx, New York, United States
Lab-grown red blood cells (lgRBCs) have the potential to supplement diagnostic and transfusion applications and serve as therapeutic drug delivery vehicles. However, clinical translation will require production at substantially higher cell densities than currently achievable. We previously developed induced pluripotent stem cell-derived self-renewing erythroblasts carrying activating KIT and JAK2 mutations that proliferate without cytokines and differentiate efficiently into enucleated lgRBCs. In a hollow-fiber bioreactor, these cells achieved densities exceeding 3–4 × 10⁸ cells/mL while maintaining enucleation efficiency and hemoglobin expression comparable to conventional low-density cultures. Building on this platform, we investigated key biological and engineering parameters that may enable scale-up toward a target density of 5 × 10⁹ cells/mL.

To optimize the biological environment, incubator CO₂ was varied to generate media pH values ranging from 7.2 to 7.6. Terminal differentiation was maximal at pH 7.3–7.4. Because glutamine metabolism contributes to ammonia accumulation during high-density culture, glutamine concentration was also evaluated. Reducing glutamine from 4 to 3 mM maintained cell growth and enucleation while significantly decreasing ammonia production.

To determine whether molecular transport limits further increases in cell density, first-order mass-transfer coefficients were measured for nutrients and metabolic waste products using hollow-fiber cartridges with PES or PVDF membranes and pore sizes ranging from 0.1 to 0.65 µm. Across two independent small-molecule transport studies, mass transfer increased with pore size, with an approximately threefold difference between the smallest and largest pore configurations.

Additional experiments evaluated the effects of media flow rate and characterized lipoprotein transport through the hollow-fiber system. Cell-specific nutrient consumption and waste-metabolite production rates were also quantified using a Nova Flex2 cell culture profiler to relate reactor transport capacity to cellular metabolic demand. These analyses demonstrated that, with optimized membrane pore size and flow conditions, diffusion of nutrients and lipids should theoretically support cell densities exceeding 5 × 10⁹ cells/mL. In contrast, ammonia generation and removal emerged as the principal barrier to achieving higher cell densities. These findings provide a quantitative framework for selecting membrane characteristics, media composition, and operating conditions for high-density lgRBC production.
Jessica Chumsky, MD: No relevant conflicts of interest to declare.